StockData
Annexon, Inc. logo

Annexon, Inc. (ANNX) company profile

ANNXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 5/30
$3.47−0.10 (-2.80%)

Close on Nov 17, 2026Market cap $709.42MP/E –Yield 0.00%

About Annexon

Pharmaceutical Preparations, SIC 2834

Annexon, Inc. is a clinical-stage biopharmaceutical company that discovers and develops targeted immunotherapies for complement-mediated neuroinflammatory disorders. The company focuses on inhibiting C1q, the initiating molecule of the classical complement cascade, to treat conditions across three primary therapeutic areas: autoimmune disorders, neurodegeneration, and ophthalmology. Its product candidates include tanruprubart for Guillain-Barré syndrome, vonaprument for geographic atrophy, and ANX1502, an oral small molecule being studied for cold agglutinin disease. Annexon also evaluates therapeutic candidates for Huntington’s disease, amyotrophic lateral sclerosis, and lupus nephritis. Its treatments are designed for patients affected by severe neuroinflammatory diseases.

Annexon conducts clinical and regulatory operations internationally, with clinical trial activity spanning the United States, Europe, and Southeast Asia. The company maintains its principal executive offices in Brisbane, California.

Summary of the business section of Annexon's latest annual report, written by StockData.

Company profile

Company

Legal name
Annexon, Inc.
Headquarters
Brisbane, CA
Address
1400 Sierra Point Parkway, Bldg C, Suite 200 94005
Phone
(650) 822-5500
Employees
96, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
KPMG LLP, San Francisco, CA

Stock & identifiers

Ticker
ANNX
Exchange
Nasdaq
IPO date
Jul 24, 2020
Shares outstanding
204M, Aug 10, 2026
Public float
$244.40M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
SEC CIK
1528115
CUSIP
03589W102
ISIN
US03589W1027
FIGI
BBG007QVDFG2
Share class FIGI
BBG007QVDFH1
EIN
27-5414423

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Douglas LovePRESIDENT AND CEO, Director390,476
Ted YednockEVP & CHIEF INNOVATION OFFICER184,807
Jamie DananbergCHIEF MEDICAL OFFICER123,582
Jennifer LewEVP & CHIEF FINANCIAL OFFICER170,700
Michael OverdorfEVP & CHIEF BUSINESS OFFICER182,625
Dean Richard ArtisEVP & CHIEF SCIENTIFIC OFFICER180,093
Mark S. BlumenkranzDirector–
William A. Jones JrDirector–
Jung ChoiDirector33,000
William H. CarsonDirector78,405
William D. WaddillDirector–
Bettina M. CockroftDirector–
Muneer A. SatterDirector10,342,134
Thomas G. WiggansDirector–

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$3.58M$5.08M$1.36M$20–
FY2024$3.67M$4.37M$1.56M$21–
FY2023$2.45M$1.20M$1.48M$18–
FY2022$3.58M$272.10K$1.42M$21–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Douglas Love
President & Chief Executive Officer
$670.83K–$2.52M$371.25K$14.86K$3.58M-3%
Ted Yednock
Executive Vice President and Chief Innovation Officer
$497.58K$112.41K$528.85K$200.30K$39.91K$1.38M-12%
Jennifer Lew
Executive Vice President and Chief Financial Officer
$495.82K$112.41K$528.85K$200.20K$4.00K$1.34M–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jul 24, 2020
Offer price
$17.00
Securities offered
14,750,000
Gross proceeds
$250.75M
Exchange
Nasdaq
First trading day
Jul 24, 2020
First-day close
$17.76+4.5%
Lock-up ends (est.)
Jan 20, 2021

“The initial public offering price is $17.00 per share of common stock.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 96 full-time employees, 77 of whom were primarily engaged in research and development activities.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?